Tikcro Technologies (TIKRF)

Overall impact
B (75)

Commentary

Tikcro Technologies is a strong overall performer. With a 'B' rating of 75.3 for overall impact (89th percentile compared to all companies), Tikcro Technologies ranks 142nd out of 585 industry peers, behind Biogen, Amgen, Regeneron Pharmaceuticals and 138 others, and ahead of Grifols, Ionis Pharmaceuticals, Gilead Sciences and 440 others. On top material causes for Tikcro Technologies's industry (Pharmaceuticals & Biotech), Tikcro Technologies performs well in Child and Maternal Health (95.0 score), Access to Affordable Healthcare (95.9), Child and Maternal Health (85.5) and 5 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (35.7 score).
Impact
Cause TIKRF
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1999
Employees
4
Sector
Health Care
Industry
Biotechnology
Sub-industry
Biotechnology
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Israel
Share classes
TIKRF
Description
Tikcro Technologies Ltd. focuses on the development of biotechnology projects in Israel. It offers anti-cytotoxic T-lymphocyte-associated protein 4 for cancer immune treatment. The company was formerly known as Tioga Technologies Ltd. and changed its name to Tikcro Technologies Ltd. in September 2003. Tikcro Technologies Ltd. was founded in 1999 and is headquartered in Hadera, Israel.
Material causes
Ethos considers the following causes material for Tikcro Technologies, based on its industry sub-industry Biotechnology. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.